Friday’s Midday Stock Update: American Green Inc (ERBB), OHR Pharmaceutical (OHRP), Karyopharm Therapeutics (KPTI), Dynavax (DVAX), OncoSec Medical (ONCS)
By Carrie Williams So far Friday, July 5, NASDAQ is up 0.96% and the S&P is up 0.32%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBB – Research Report), OHR Pharmaceutical (OHRP – Research Report), Karyopharm Therapeutics (KPTI – Research Report), Dynavax (DVAX – Research Report) and OncoSec Medical (ONCS – Research Report).
American Green Inc is down -33.33% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.
OHR Pharmaceutical is up 15.82% in midday trading to $3.66. Shares opened today at $3.16. The company has a 52-week low of $1.58 and a 52-week high of $0.00.
Karyopharm Therapeutics is down -12.13% in midday trading to $8.91. Shares opened today at $10.14. The company has a 52-week low of $3.92 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $21.50, marking a 112.03% potential upside from current levels. In a report released today, Wedbush analyst David Nierengarten maintained a Buy rating on KPTI, with a price target of $11, which represents a potential upside of 8% from where the stock is currently trading.
See today’s analyst top recommended stocks >>
Dynavax is down -9.78% in midday trading to $4.11. Shares opened today at $4.55. The company has a 52-week low of $3.57 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $23.67, marking a 420.22% potential upside from current levels. In a report issued on June 17, William Blair analyst Matt Phipps reiterated a Buy rating on DVAX.
OncoSec Medical is up 8.85% in midday trading to $2.46. Shares opened today at $2.26. The company has a 52-week low of $2.17 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $10.00, marking a 342.48% potential upside from current levels. In a report issued on June 28, Maxim Group analyst Jason McCarthy maintained a Buy rating on ONCS, with a price target of $10, which implies an upside of 342% from current levels. Over the last 3 months, the insider sentiment on OncoSec Medical has been positive based on 15 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.